Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/2/118 |
| _version_ | 1797520769014562816 |
|---|---|
| author | Fernando Franco María Guirado Natividad Martínez-Banaclocha Josep Gumà Javier Lavernia José Gómez-Codina Delvys Rodriguez-Abreu Fani Martínez Enrique Barrajón Miriam Méndez Virginia Calvo Mariano Provencio |
| author_facet | Fernando Franco María Guirado Natividad Martínez-Banaclocha Josep Gumà Javier Lavernia José Gómez-Codina Delvys Rodriguez-Abreu Fani Martínez Enrique Barrajón Miriam Méndez Virginia Calvo Mariano Provencio |
| author_sort | Fernando Franco |
| collection | DOAJ |
| description | The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly patients with lung tumour involvement and haematological neoplasms. The Spanish Lymphoma Oncology Group (GOTEL) carried out a multicenter study of SARS-CoV-2 seroprevalence in patients with lymphoma. Results: A total of 150 patients were included between 22 May and 11 June 2020. The mean age was 65 years (range 17–89), 70 women (46.5%) and 80 men (53, 5%). At the time of diagnosis of lymphoma, 13 cases were stage I (9%), 27 (18%) stage II, 37 (24.5%) stage III, and 73 (48.5%) stage IV, while 6.6% had a primary extranodal origin. A total of 10 cases with positive serology for SARS-CoV-2 were identified, which is a prevalence of 6% in this population. None of the patients required intensive care unit management and all fully recovered from the infection. Conclusion: IgG antibody seroprevalence in lymphoma patients appears similar to that of the general population and does not show greater aggressiveness. |
| first_indexed | 2024-03-10T08:01:18Z |
| format | Article |
| id | doaj.art-b2284b85a76f40379efc0371fc0ca006 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:01:18Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-b2284b85a76f40379efc0371fc0ca0062023-11-22T11:27:20ZengMDPI AGCurrent Oncology1198-00521718-77292021-03-012821249125510.3390/curroncol28020118Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)Fernando Franco0María Guirado1Natividad Martínez-Banaclocha2Josep Gumà3Javier Lavernia4José Gómez-Codina5Delvys Rodriguez-Abreu6Fani Martínez7Enrique Barrajón8Miriam Méndez9Virginia Calvo10Mariano Provencio11Medical Oncology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, SpainMedical Oncology Department, Hospital General Universitario de Elche, 03203 Elche, SpainMedical Oncology Department, Hospital General Universitario de Alicante, 03010 Alicante, SpainMedical Oncology Department, Hospital Universitari Sant Joan de Reus. URV. IISPV, 43204 Reus, SpainMedical Oncology Department, Instituto Valenciano de Oncología, 46009 Valencia, SpainMedical Oncology Department, Hospital Universitario la Fe, 46026 Valencia, SpainMedical Oncology Department, Hospital Universitario Insular de Gran Canaria, 35016 Las Palmas de Gran Canaria, SpainMedical Oncology Department, Hospital Universitari Sant Joan de Reus. URV. IISPV, 43204 Reus, SpainMedical Oncology Department, Hospital General Universitario de Elche, 03203 Elche, SpainMedical Oncology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, SpainMedical Oncology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, SpainMedical Oncology Department, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, SpainThe new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly patients with lung tumour involvement and haematological neoplasms. The Spanish Lymphoma Oncology Group (GOTEL) carried out a multicenter study of SARS-CoV-2 seroprevalence in patients with lymphoma. Results: A total of 150 patients were included between 22 May and 11 June 2020. The mean age was 65 years (range 17–89), 70 women (46.5%) and 80 men (53, 5%). At the time of diagnosis of lymphoma, 13 cases were stage I (9%), 27 (18%) stage II, 37 (24.5%) stage III, and 73 (48.5%) stage IV, while 6.6% had a primary extranodal origin. A total of 10 cases with positive serology for SARS-CoV-2 were identified, which is a prevalence of 6% in this population. None of the patients required intensive care unit management and all fully recovered from the infection. Conclusion: IgG antibody seroprevalence in lymphoma patients appears similar to that of the general population and does not show greater aggressiveness.https://www.mdpi.com/1718-7729/28/2/118lymphomainfection of SARS-CoV-2Covid-19 |
| spellingShingle | Fernando Franco María Guirado Natividad Martínez-Banaclocha Josep Gumà Javier Lavernia José Gómez-Codina Delvys Rodriguez-Abreu Fani Martínez Enrique Barrajón Miriam Méndez Virginia Calvo Mariano Provencio Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) Current Oncology lymphoma infection of SARS-CoV-2 Covid-19 |
| title | Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) |
| title_full | Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) |
| title_fullStr | Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) |
| title_full_unstemmed | Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) |
| title_short | Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel) |
| title_sort | multicenter study of the seroprevalence of antibodies against covid 19 in patients with lymphoma an analysis of the oncological group for the treatment and study of lymphomas gotel |
| topic | lymphoma infection of SARS-CoV-2 Covid-19 |
| url | https://www.mdpi.com/1718-7729/28/2/118 |
| work_keys_str_mv | AT fernandofranco multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT mariaguirado multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT natividadmartinezbanaclocha multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT josepguma multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT javierlavernia multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT josegomezcodina multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT delvysrodriguezabreu multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT fanimartinez multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT enriquebarrajon multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT miriammendez multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT virginiacalvo multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel AT marianoprovencio multicenterstudyoftheseroprevalenceofantibodiesagainstcovid19inpatientswithlymphomaananalysisoftheoncologicalgroupforthetreatmentandstudyoflymphomasgotel |